ALVOTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating Alvotech on Behalf of Alvotech Stockholders and Encourages Investors to Contact the Firm

Core Points - Bragar Eagel & Squire, P.C. is investigating potential claims against Alvotech for possible violations of federal securities laws and unlawful business practices [1][2] - Alvotech's stock experienced a significant decline of 34.25%, dropping $2.62 to close at $5.03 per share following a Complete Response Letter from the FDA regarding its AVT05 BLA biologics license application [2] Investigation Details - The investigation was prompted by a failed facility inspection in July 2025, which led to the FDA's Complete Response Letter received on November 3, 2025 [2] - Investors who suffered losses and have information regarding Alvotech are encouraged to contact the law firm for further discussion on their rights and potential claims [3] About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with a focus on representing individual and institutional investors in various types of litigation [4] - The firm operates in multiple states, including New York, South Carolina, and California, and offers services without cost or obligation to the investors [4]